PROJECT NARRATIVE Proinflammatory Th17 and microglial cells have been implicated in Alzheimer’s disease (AD). However, the understanding of their roles in neuroinflammation that drive the AD pathogenesis is limited. In this study we will investigate the mechanisms underlying the regulation of peripheral Th17 and central microglial cells in AD development and progression, as well as the therapeutic potential of pharmacological inhibition of the production of proinflammatory Th17 and microglial cytokines as new immunomodulation therapy for AD.
|Effective start/end date||15/06/21 → 28/02/23|
- National Institute on Aging: $844,476.00
- National Institute on Aging: $753,195.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.